共 50 条
- [1] Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)Fuchs, Charles S.Denker, Andrew E.Tabernero, JosepVan Cutsem, EricOhtsu, AtsushiLam, BaohoangKoshiji, MinoriBang, Yung-Jue
- [2] Phase 2 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction adenocarcinomaANNALS OF ONCOLOGY, 2015, 26 : 69 - 69Van Cutsem, E.Fuchs, C. S.Denker, A. E.Tabernero, J.Ohtsu, A.Lam, B.Koshiji, M.Bang, Y. -J.
- [3] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinomaANNALS OF ONCOLOGY, 2015, 26 : 69 - 69Ohtsu, A.Tabernero, J.Bang, Y. -J.Fuchs, C. S.Sun, L.Wang, Z.Csiki, I.Koshiji, M.Van Cutsem, E.
- [4] KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)Tabernero, JosepBang, Yung-JueFuchs, Charles S.Ohtsu, AtsushiKher, UmaLam, BaohoangKoshiji, MinoriVan Cutsem, Eric
- [5] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)Ohtsu, AtsushiTabernero, JosepBang, Yung-JueFuchs, Charles S.Sun, LindaWang, ZhenCsiki, IldikoKoshiji, MinoriVan Cutsem, Eric
- [6] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Randomized, open-label, phase 3 KEYNOTE-061 studyANNALS OF ONCOLOGY, 2015, 26Ohtsu, A.Tabernero, J.Bang, Y. -J.Fuchs, C.Sun, L.Wang, Z.Csiki, I.Koshiji, M.Van Cutsem, E.
- [7] Pembrolizumab (MK-3475) for previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase II KEYNOTE-180 study.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)Shah, Manish A.Bennouna, JaafarShen, LinEnzinger, Peter C.Li, QiaoCsiki, IldikoKoshiji, MinoriDoi, Toshihiko
- [8] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 studyGastric Cancer, 2019, 22 : 828 - 837Yung-Jue BangYoon-Koo KangDaniel V. CatenacciKei MuroCharles S. FuchsRavit GevaHiroki HaraTalia GolanMarcelo GarridoShadia I. JalalChristophe BorgToshihiko DoiHarry H. YoonMary J. SavageJiangdian WangRita P. DalalSukrut ShahZev A. WainbergHyun Cheol Chung
- [9] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 studyGASTRIC CANCER, 2019, 22 (04) : 828 - 837Bang, Yung-JueKang, Yoon-KooCatenacci, Daniel V.Muro, KeiFuchs, Charles S.Geva, RavitHara, HirokiGolan, TaliaGarrido, MarceloJalal, Shadia I.Borg, ChristopheDoi, ToshihikoYoon, Harry H.Savage, Mary J.Wang, JiangdianDalal, Rita P.Shah, SukrutWainberg, Zev A.Chung, Hyun Cheol
- [10] KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancerANNALS OF ONCOLOGY, 2017, 28Wainberg, Z. A.Jalal, S.Muro, K.Yoon, H. H.Garrido, M.Golan, T.Doi, T.Catenacci, D. V.Geva, R.Ku, G.Bleeker, J.Bang, Y-J.Hara, H.Chung, H. C.Savage, M.Wang, J.Koshiji, M.Dalal, R.Fuchs, C. S.